Cushing's Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat

Caio Teixeira Heleno, Seung Pyo D. Hong, Hyung Gyo Cho, Min Jeong Kim, Yeonggyeong Park, Young Kwang Chae*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Cushing's syndrome (CS), secondary to paraneoplastic syndrome, is more commonly seen in small cell lung cancer but never before reported in epidermal growth factor receptor-mutated adenocarcinoma of the lung. Here, we present a case of a patient whose symptoms of hypokalemia, hypertension, and progressive abnormal glucose levels led to further workup that revealed adrenocorticotropic hormone-dependent hypercortisolism. Her cortisol levels dropped after 1 month of osilodrostat treatment, while lung cancer was treated with osimertinib. The use of osilodrostat in paraneoplastic CS has been previously reported in only 3 patients.

Original languageEnglish (US)
Pages (from-to)124-128
Number of pages5
JournalCase Reports in Oncology
StateAccepted/In press - 2023


  • Case report
  • Ectopic adrenocorticotropic hormone-dependent Cushing
  • Epidermal growth factor receptor
  • Osilodrostat

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Cushing's Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat'. Together they form a unique fingerprint.

Cite this